Androgen Receptor Mediates Dopamine Agonist Resistance by Regulating Intracellular Reactive Oxygen Species in Prolactin-Secreting Pituitary Adenoma
Antioxidants & Redox Signaling · 2025
DOI: 10.1089/ars.2024.0611 ↗Kurz gefasst
Fachartikel in der Zeitschrift Antioxidants & Redox Signaling, 2025. Verfasst von Linpeng Xu und 10 weiteren Autor:innen. Beteiligte Einrichtung: Sino-German Neuro-Oncology Molecular Laboratory, Department of Neurosurgery, Tongji Hospital of Tongji Medical College of Huazhong University of Scie…. Hauptthemen laut MEDLINE: Reactive Oxygen Species, Pituitary Neoplasms, Receptors, Androgen, Dopamine Agonists. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 70 Literaturangaben.
Abstract (Originalsprache)
Aims
Dopamine agonists (DAs) are the first-line treatment for patients with prolactin-secreting pituitary adenoma (PRL adenoma). However, a subset of individuals exhibits poor responses, known as DA resistance. Previous studies have reported that DA resistance is more prevalent in male patients. This study aims to investigate the relationship between androgen receptor (AR) expression and DA resistance, as well as to explore underlying mechanisms of AR-mediated DA resistance.
Results
Our results demonstrated that patients with higher AR expression exhibit greater resistance to DA in our cohort of DA-resistant PRL adenoma. Furthermore, AR was found to be involved in cell proliferation, PRL secretion, and resistance to bromocriptine (BRC) both in vitro and in vivo . Mechanistically, we demonstrated that intracellular reactive oxygen species (ROS) function as upstream mediators of apoptosis and ferroptosis following BRC treatment. As a ligand-dependent transcription factor, AR could translocate to the nucleus and transcriptionally promote NFE2-like bZIP transcription factor 2 (NRF2) expression, which regulates intracellular ROS levels, thereby enhancing cell viability and conferring DA resistance to pituitary adenoma (PA) cells. Finally, AR targeting agents were used to inhibit AR signaling, downregulate NRF2 transcription, and sensitize PA cells to BRC treatment. Conclusion and Innovation: We demonstrated that AR plays a crucial role in mediating DA resistance in PRL adenoma. Mechanistically, AR promotes cell proliferation and PRL secretion and confers drug resistance by transcriptionally regulating NRF2 expression to maintain redox homeostasis in PA cells. Finally, combining AR targeting agents with BRC shows promise as a therapeutic strategy for treating PRL adenomas. Antioxid. Redox Signal. 42, 954–972.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Sino-German Neuro-Oncology Molecular Laboratory, Department of Neurosurgery, Tongji Hospital of Tongji Medical College of Huazhong University of Science and Technology, Wuhan, China.
- Hubei Key Laboratory of Neural Injury and Functional Reconstruction, Huazhong University of Science and Technology, Wuhan, China.
- Department of Orthopedics, Tongji Hospital of Tongji Medical College of Huazhong University of Science and Technology, Wuhan, China.
ORCID-Profile: Linpeng Xu
Zitieren
APA
Xu, L., Lei, Z., Wang, Q., Jiang, Q., Xing, B., Li, X., Guo, X., Wang, Z., Li, S., Huang, Y., & Lei, T. (2025). Androgen Receptor Mediates Dopamine Agonist Resistance by Regulating Intracellular Reactive Oxygen Species in Prolactin-Secreting Pituitary Adenoma. Antioxidants & Redox Signaling. https://doi.org/10.1089/ars.2024.0611
Vancouver
Xu L, Lei Z, Wang Q, Jiang Q, Xing B, Li X, et al. Androgen Receptor Mediates Dopamine Agonist Resistance by Regulating Intracellular Reactive Oxygen Species in Prolactin-Secreting Pituitary Adenoma. Antioxidants & Redox Signaling. 2025. doi:10.1089/ars.2024.0611
BibTeX
@article{Xu2025,
author = {Xu, Linpeng and Lei, Zhuowei and Wang, Quanji and Jiang, Qian and Xing, Biao and Li, Xingbo and Guo, Xiang and Wang, Zihan and Li, Sihan and Huang, Yimin and Lei, Ting},
title = {Androgen Receptor Mediates Dopamine Agonist Resistance by Regulating Intracellular Reactive Oxygen Species in Prolactin-Secreting Pituitary Adenoma},
journal = {Antioxidants & Redox Signaling},
year = {2025},
doi = {10.1089/ars.2024.0611}
}
EUVIMED